Soligenix, Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical issuer developing rare-disease therapeutics and public health vaccine candidates. Form 8-K reports disclose clinical and regulatory events for HyBryte in cutaneous T-cell lymphoma and SGX945 (dusquetide) in Behçet's Disease, including trial-result announcements, orphan drug designations and corporate progress updates.
Registration statements and material-event filings describe Soligenix's capital structure, including common stock, warrants, preferred stock and at-the-market or public offering activity. The filing record also covers Nasdaq continued-listing compliance, material agreements, governance matters, operating and financial results, risk factors and shareholder voting matters tied to its drug-development pipeline.
Soligenix, Inc. is asking stockholders to approve several governance and capital-structure changes at its September 17, 2026 virtual annual meeting. The agenda includes electing five directors, a reverse stock split at a ratio between 1-for-2 and 1-for-20, and increasing authorized common shares from 75,000,000 to 125,000,000.
The company highlights a difficult year marked by discontinuation of the Phase 3 FLASH2 study of HyBryte for early-stage CTCL, but points to a Phase 2 Behçet’s disease study of SGX945 with promising preliminary efficacy and a ThermoVax heat-stable vaccine platform, including a Bundibugyo Ebola program supported by government efforts. Management states it is actively evaluating strategic alternatives such as partnerships, licensing, mergers, acquisitions and financings, while noting there are no definitive agreements.
Soligenix emphasizes the importance of maintaining its Nasdaq listing after receiving notice that its share price fell below the $1.00 minimum bid. The Board recommends the reverse split to help regain compliance and the authorized share increase to support potential M&A and other corporate development activities. As of July 20, 2026, 21,765,479 common shares were outstanding.
Soligenix, Inc. is asking stockholders at the 2026 virtual annual meeting to approve several governance and capital proposals, centered on preserving its Nasdaq listing and supporting strategic flexibility. An amended proxy description clarifies that, in the proposed reverse stock split, stockholders otherwise entitled to fractional shares of common stock will instead receive a cash payment based on recent trading prices, rather than having fractional shares rounded up.
The Board seeks authority, exercisable for up to one year, to implement a reverse stock split of the issued and outstanding common stock at a ratio between 1‑for‑2 and 1‑for‑20, aimed at lifting the share price to satisfy Nasdaq’s $1.00 minimum bid requirement after a June 2026 deficiency notice. A separate proposal would increase authorized common shares from 75,000,000 to 125,000,000 for potential mergers, acquisitions, financings and other corporate purposes. Stockholders will also vote on electing five directors, advisory say‑on‑pay and frequency, auditor ratification, and an adjournment proposal.
Soligenix, Inc. is a Nasdaq-listed biopharmaceutical company focused on rare diseases and public health vaccines. The CEO’s letter notes a challenging year, including discontinuation of the Phase 3 FLASH2 HyBryte™ CTCL study, but highlights a diversified pipeline, including SGX945 for Behçet’s disease with promising Phase 2 signals and the ThermoVax® heat-stable vaccine platform supported by government biodefense efforts.
For the September 17, 2026 virtual annual meeting, stockholders are asked to elect five incumbent directors and vote on several key items, notably a discretionary reverse stock split of common stock at a ratio between 1‑for‑2 and 1‑for‑20 and an increase in authorized common shares from 75,000,000 to 125,000,000. The board links these measures to maintaining Nasdaq listing and supporting future strategic and financing flexibility. Advisory votes on executive pay and its frequency, auditor ratification, and an adjournment proposal are also on the agenda. The board unanimously recommends approval of all proposals.
Soligenix, Inc. increased by $2,500,000 the maximum aggregate amount of its common stock that may be issued under its at-the-market sales agreement with Rodman & Renshaw LLC, through a new prospectus supplement. The company previously sold about $6,234,000 of common stock under earlier supplements that covered up to $6,406,000 of shares. The 8-K also files the related legal opinion from Duane Morris LLP as an exhibit.
Soligenix, Inc. amends its prior prospectus supplements to reset the available At-The-Market capacity under its Sales Agreement with Rodman & Renshaw LLC to $2,500,000. This Prospectus Supplement replaces unsold amounts under the Prior Prospectus and permits the company to offer and sell common stock from time to time under the Sales Agreement.
The Prior Prospectus had authorized up to an aggregate offering price of $6,406,000, of which shares with an aggregate price of approximately $6,234,000 were sold. The company reports a public float of $30,702,784 based on 21,621,679 shares held by non-affiliates and a per-share price of $1.42 as of April 27, 2026. Pursuant to Form S-3 General Instruction I.B.6, Soligenix discloses it has sold securities with an aggregate market value of $7,700,914 in the prior 12-calendar-month period.
SOLIGENIX, INC. ownership disclosure: MJL Manager LLC reports beneficial ownership of 893,588 shares (5.2%), Michael Liu reports 983,588 shares (5.7%), and Capuchin Capital Fund LP reports 539,737 shares (3.1%). The filing states Michael Liu has sole voting and dispositive power over 90,000 shares and shared voting/dispositive power over the larger pooled positions. The filing notes MJL Manager LLC is the general partner of Capuchin Capital Fund LP and manages discretionary accounts with authority to direct voting and disposition of shares.
Soligenix, Inc. is ending development of its HyBryte™ therapy and has received a Nasdaq warning about its share price. The board decided on June 11, 2026 to terminate the HyBryte™ program after an interim analysis of the Phase 3 FLASH2 trial recommended stopping for futility. The company will wind down the study and related work and expects about $70,000 in close‑out charges. Soligenix also received notice on June 10, 2026 that its stock has traded below Nasdaq’s $1.00 minimum bid price for 30 consecutive business days, triggering a 180‑day grace period, until December 7, 2026, to regain compliance. If needed and other listing conditions are met, Soligenix may seek an additional 180‑day period, potentially via a reverse stock split. In connection with ending HyBryte™, Consulting Chief Medical Officer Dr. Richard Straube’s role will wind down, with responsibilities shifting to Medical Director Dr. Christopher Pullion. The company plans to evaluate strategic options, including mergers and acquisitions, and focus on other pipeline assets such as dusquetide (SGX945) for Behçet’s Disease.
Soligenix, Inc. filed a prospectus supplement to increase the maximum aggregate offering amount of its common stock under an existing At Market Issuance Sales Agreement with Rodman & Renshaw LLC by an additional $2,956,000.
The company previously sold approximately $3,445,000 of common stock under this agreement pursuant to an earlier prospectus supplement. A legal opinion from Duane Morris LLP covering the additional $2,956,000 of common stock is included as an exhibit, along with the related consent and an Inline XBRL cover page data file.
Soligenix, Inc. amends its prospectus supplement to set an at-the-market offering capacity of $2,956,000 of common stock under the Sales Agreement with Rodman & Renshaw LLC. The company reports a public float of $24,511,625 based on 17,261,708 shares held by non-affiliates at $1.42 per share as of April 27, 2026. The supplement notes prior sales of $5,214,498 under the Form S-3 instruction during the preceding 12-month period and lists a last reported sale price of $0.87 on May 27, 2026.